Long-form guides built to rank and educate
Comparisons, category explainers, and lab literacy — the content layer that captures search intent beyond single compound names.
Melanotan I vs Melanotan II: An Educational Comparison
An educational comparison of two melanocortin peptides—receptor selectivity (MC1R vs MC1R and MC4R), afamelanotide's narrow approval, and the unapproved status of research use.
Peptide Purity and Testing: How Identity Is Verified
How peptide purity and identity are assessed in the lab—HPLC, mass spectrometry, net peptide content, TFA counterion, and the red flags that undermine a certificate of analysis.
Choosing a Research Peptide Supplier: Quality and Compliance Markers
A lab-literacy guide to the quality and compliance markers to look for in a research peptide supplier—batch COAs, chromatograms, storage, and RUO framing. Educational, not an endorsement.
What Are Research Peptides? A Clear Educational Guide
Learn what “research peptides” means, how they differ from approved peptide drugs, quality markers (COA, purity), and how to study them responsibly.
BPC-157 vs TB-500: Differences, Research Context & Comparison
Side-by-side educational comparison of BPC-157 and TB-500—sequences, research themes, stacking discussions, and evidence limits.
GLP-1 Peptides Explained: GLP-1, Semaglutide, Tirzepatide, Retatrutide
From endogenous GLP-1 to dual and triple agonists—an educational map of incretin peptide science and metabolic drug design.
Are Peptides Legal in Canada? A Regulatory Guide
An educational overview of how Health Canada regulates peptides—drug authorization, DINs, the “research use only” gray area, and import ambiguity. Not legal advice.
Semaglutide vs Tirzepatide: Structure, Receptors, Half-Life and the SURMOUNT-5 Head-to-Head
A mechanistic comparison of semaglutide (single GLP-1 agonist) and tirzepatide (dual GIP/GLP-1 agonist): sequences, side chains, half-lives, and what the only head-to-head trial, SURMOUNT-5, actually showed.
Retatrutide vs Tirzepatide: Triple vs Dual Agonist — Structure, Half-Life, Trial Data
Retatrutide and tirzepatide are 39-residue siblings built on the same GIP scaffold. This guide compares their sequences, receptor profiles, half-lives, phase 2/3 weight-loss data and approval status — with the caveat that no head-to-head trial exists.
Semaglutide vs Liraglutide: A Mechanistic GLP-1 Comparison
An educational comparison of semaglutide and liraglutide—two approved GLP-1 receptor agonists—covering structure, half-life, dosing cadence, and approval status. Not medical advice.
Collagen Peptides Explained: A Consumer-Friendly Guide
A plain-language explainer on hydrolyzed collagen peptides—what they are, collagen types I, II and III, and how these dietary ingredients differ from research peptides. Educational only, not medical advice.
Peptide Safety and Risks: A Balanced Educational Overview
An objective, balanced overview of what research does and does not establish about peptide risks—unknowns, purity and contamination concerns, and why unapproved compounds carry uncertainty. Not reassurance and not medical advice.
Peptides for Beginners: A Clear Educational Foundation
A beginner-friendly primer on what peptides are, how they differ from proteins and SARMs, approved medicines vs research materials, and how to learn responsibly.
GLP-1 vs GIP vs Glucagon: Incretin Receptor Classes Explained
An educational overview of the incretin and metabolic receptor classes—GLP-1, GIP, and glucagon—and how single, dual, and triple receptor agonism differ mechanistically.
GH Secretagogue Peptides Explained: CJC-1295, Ipamorelin, GHRPs
Educational overview of growth hormone secretagogue peptides—GHRH analogs vs GHRPs, DAC vs no DAC, receptors, and research context.
How to Read a Peptide COA (Certificate of Analysis)
Understand HPLC purity, mass spectrometry identity, net peptide content, TFA salts, and red flags on research peptide COAs.
CJC-1295 vs Ipamorelin: Growth Hormone Secretagogue Comparison
An educational comparison of CJC-1295 (a GHRH analog) and ipamorelin (a selective ghrelin/GHS-R agonist) as research compounds—receptors, selectivity, and framing. Not medical advice.
Peptides vs SARMs: A Science-Literacy Comparison
An educational look at how peptides (amino-acid chains acting through receptor and signaling biology) differ from SARMs (non-peptide small molecules targeting the androgen receptor). Framed as science literacy, not usage advice.
CJC-1295 vs Sermorelin: Comparing GHRH Analogs
An educational comparison of CJC-1295 and sermorelin—two GHRH-analog research compounds—covering DAC vs no-DAC design, half-life concepts, and framing. Not medical advice.
Retatrutide Side Effects: What the Clinical Trials Actually Reported
A sourced summary of retatrutide's adverse-event data from the phase 2 obesity and diabetes trials and the first phase 3 report — gastrointestinal effects, heart rate, skin sensitivity, discontinuations — plus the class warnings that apply to every incretin and what remains unknown.
Retatrutide Dosing: Every Schedule Used in the Published Trials (Not a Protocol)
The dose arms, starting doses, escalation steps and durations used in retatrutide's phase 2 obesity trial, phase 2 diabetes trial and phase 3 TRANSCEND-T2D-1, with the results each arm produced — plus a concentration calculator for the arithmetic of reconstitution. Descriptive, not prescriptive.
Retatrutide Dosage Calculator: Reconstitution and Concentration Math (mg, mL, Units)
An educational calculator for the arithmetic behind lyophilised retatrutide: how vial mass and diluent volume set the concentration, and what volume any amount corresponds to on a U-100 syringe. It computes; it does not recommend. Trial doses and their results are on the dosing guide.
Retatrutide vs Semaglutide (Ozempic, Wegovy): Triple Agonist vs GLP-1 — Structure, Half-Life, Trial Data
Semaglutide is the approved GLP-1 analogue in Ozempic and Wegovy; retatrutide is an investigational GIP/GLP-1/glucagon triple agonist. This guide compares their sequences, receptors, half-lives, weight-loss and outcomes evidence, side effects and approval status — with no head-to-head trial to lean on.
How Does Retatrutide Work? Mechanism of Action at Three Receptors
Retatrutide is one peptide that activates three metabolic hormone receptors — GIP, GLP-1 and glucagon. This guide explains what each receptor does, why the three activities are deliberately unbalanced, how the design keeps glucose falling despite glucagon agonism, and how the trial results line up with the mechanism.
What Is the “Wolverine” Peptide? BPC-157 + TB-500, and What the Evidence Actually Shows
“Wolverine peptide” (or “Wolverine stack”) is a vendor nickname for BPC-157 combined with TB-500. This guide explains what each component is, what has actually been studied in humans (very little), what a rat combination study found and what remains untested in humans, and where it stands legally.
What Is the “GLOW” Peptide? GHK-Cu + BPC-157 + TB-500, Explained From the Evidence
“GLOW peptide” is a vendor blend name for GHK-Cu, BPC-157 and TB-500 in one vial. This guide explains each component, the linked cellular and animal evidence, the gaps for a three-way injectable blend, and product-specific authorization.
What Is the “KLOW” Peptide? KPV + GHK-Cu + BPC-157 + TB-500, Component by Component
“KLOW peptide” is a four-peptide vendor blend: KPV, GHK-Cu, BPC-157 and TB-500. This guide explains what each is, what has been studied in humans (very little beyond topical GHK-Cu), why a four-way mix is untested, and where it stands legally.
Is MK-677 (Ibutamoren) a Peptide? No — It Is an Oral Small-Molecule Ghrelin Mimetic. What the Trials Showed
MK-677 (ibutamoren) is sold next to peptides and stacked with them, but it is a small synthetic molecule that activates the ghrelin receptor by mouth. This guide explains what it is, how it differs from GHRH and GHRP peptides, what its clinical trials showed — including the safety signal that stopped one — and its regulatory status.
Is Tirzepatide a Peptide? Yes — a 39-Residue Dual Incretin Agonist, and Here Is Its Chemistry
Tirzepatide is a peptide: a synthetic 39-amino-acid chain of about 4,813.5 Da, built on the GIP backbone rather than GLP-1, carrying two Aib substitutions and a C20 fatty diacid. This guide sets out what it is made of, why each modification is there, and how it differs from semaglutide.
Peptide Storage & Stability: Lyophilized vs In Solution
Educational guide to storing research peptides—temperature, moisture, freeze-thaw, light, and why lyophilized powders differ from solutions.
Why Peptides Have Short Half-Lives (And How Engineers Fix It)
Proteases, renal clearance, DPP-4, PEGylation, lipidation, cyclization—educational guide to peptide pharmacokinetics concepts.
How to Reconstitute Peptides: A Laboratory Overview
An educational, research-use-only overview of peptide reconstitution concepts—lyophilized powder, bacteriostatic water, gentle mixing, sterile technique, and storage. No human dosing instructions.
CagriSema Explained: Cagrilintide + Semaglutide, Mechanism and REDEFINE Trial Results
CagriSema combines cagrilintide (a long-acting amylin analogue) with semaglutide (a GLP-1 agonist) in one weekly injection. This guide explains why two receptors beat one, what REDEFINE 1 showed (−20.4% at 68 weeks), how it compares with tirzepatide and retatrutide, and where approval stands.
GLP-1 and Incretin Peptide Half-Lives Compared: From 2 Minutes to 8 Days
A sourced table of the plasma half-lives of native GLP-1, exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide, retatrutide, cagrilintide and the newer co-agonists — and the three engineering strategies (DPP-4 resistance, albumin binding, Fc fusion) that stretch minutes into a week.
Orforglipron vs Peptide GLP-1 Agonists: Small Molecule vs Peptide, Explained
Orforglipron (Foundayo, FDA-approved in the US in April 2026) is the first non-peptide GLP-1 receptor agonist. This guide explains how a small molecule activates a peptide receptor, why that allows a pill without food or water restrictions, how ATTAIN-1 results compare with semaglutide and tirzepatide trials, and what the trade-offs are.
What Is “GLP-3”? There Is No Such Hormone — the Name Means Retatrutide
“GLP-3” and “GLP-3 peptide” are internet nicknames for retatrutide, the investigational GIP/GLP-1/glucagon triple agonist. This guide explains where the name came from, why it is scientifically wrong, what the real proglucagon-derived peptides are, and how to search the literature without it.
Cagrilintide Dosage and Side Effects: What the Phase 2 and REDEFINE Trials Used and Reported
The once-weekly doses cagrilintide was tested at (0.3–4.5 mg alone; 2.4 mg with semaglutide as CagriSema), how the trials escalated, the weight loss each arm produced, and the adverse events reported — gastrointestinal effects and injection-site reactions above all. Descriptive, not prescriptive.
Is Tesofensine a Peptide? No — It Is a Small-Molecule Reuptake Inhibitor. What It Is and Where It Stands
Tesofensine is sold alongside peptides and often searched as one, but it is a small organic molecule that blocks serotonin, noradrenaline and dopamine reuptake. This guide explains what it is, what its phase 2 trial showed, why it stalled, and why it is not an approved medicine in the US, Canada or Europe.
Is 5-Amino-1MQ a Peptide? No — It Is a Small-Molecule NNMT Inhibitor With Only Animal Data
5-Amino-1MQ is marketed next to peptides but is a small quinolinium molecule that inhibits the enzyme NNMT. This guide explains what it is, what the mouse studies showed, why there are no human data, and its regulatory status.
Is NAD+ a Peptide? No — It Is a Coenzyme. What NAD+, NMN and NR Actually Are and What the Evidence Shows
“NAD+ peptide” is a search term with no molecule behind it: NAD+ is a nucleotide coenzyme, not a peptide. This guide explains what NAD+ is, why it appears in peptide catalogues, what the precursors NMN and NR do, what human trials have and have not shown, and the regulatory status of each.
Is Creatine a Peptide? No — It Is a Single Small Molecule Made From Three Amino Acids
Creatine is not a peptide. It is methylguanidinoacetic acid, one small molecule of about 131.1 Da with no peptide bond in it — though your body builds it from glycine, arginine and methionine, which is exactly why the question keeps coming up.
Peptide Synthesis Basics for Non-Chemists
Plain-language introduction to solid-phase peptide synthesis (SPPS), purification, and why custom peptides cost what they cost.
Cosmetic Peptides vs Research Peptides: What’s the Difference?
GHK-Cu, Matrixyl, SNAP-8 and skincare peptides versus injectable research peptides—regulation, exposure routes, and marketing language.
Ipamorelin vs GHRP-6: Selectivity, Appetite, and Receptor Profiles
How ipamorelin and GHRP-6 differ as ghrelin-receptor growth-hormone secretagogues—selectivity, appetite and cortisol effects, and why researchers characterize them differently. Educational only.
Tesamorelin vs CJC-1295: Two GHRH Analogs, Compared
Tesamorelin and CJC-1295 are both GHRH analogs, but one is an approved medicine and the other a research compound. Compare their design, half-life, and how the literature treats them. Educational only.
BPC-157: Oral vs Injectable — What the Research Actually Shows
The oral-versus-injectable question for BPC-157, framed by what preclinical research actually reports about stability, gut effects, and systemic exposure. Educational only, not a protocol.
What Is Bacteriostatic Water? Reconstitution Diluents Explained
A clear educational explainer on bacteriostatic water, sterile water, and how diluents are used to reconstitute lyophilized peptides in the lab—plus why the terminology matters. Not medical advice.
GHK-Cu and Copper Peptides: The Science of Skin and Repair
What GHK-Cu is, why copper peptides are studied in skin and wound research, and how cosmetic use differs from injectable research claims. An evidence-focused educational explainer.
Do Peptides Expire? Shelf Life, Degradation, and Stability Signals
How and why peptides degrade, what shelf life means for lyophilized powder versus reconstituted solution, and the physical signs researchers watch for. Educational stability literacy.